Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.41 |
| ▸ | HTR3B | O95264 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4297572 | 0.89 | HSD17B14 (0.48) | ALDH1A1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL3469632 | 0.89 | HSD17B14 (0.48) | ALDH1A1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL4300878 | 0.74 | PROKR1 (0.46) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3467254 | 0.72 | HSD17B14 (0.44) | ALDH1A1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL22324761 | 0.72 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NAMPT | |
| Hydrochloric Acid SCHEMBL4297856 | 0.71 | HSD17B14 (0.48) | ALDH1A1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL3436388 | 0.71 | PDK4 (0.44) | ALDH1A1SMN1; SMN2NAMPT | |
| Hydrochloric Acid SCHEMBL3466386 | 0.71 | HTR3A (0.57) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3466177 | 0.70 | HSD17B14 (0.49) | ALDH1A1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL4290842 | 0.69 | HSD17B14 (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | ALDH1A1 1207/4885SMN1; SMN2 2107/4885HTR3E 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.